Selected article for: "Antigen selection and vaccine development"

Author: Berry, Jody D; Jones, Steven; Drebot, Michael A; Andonov, Anton; Sabara, Marta; Yuan, Xin Y; Weingartl, Hana; Fernando, Lisa; Marszal, Peter; Gren, Jason; Nicolas, Brigitte; Andonova, Maya; Ranada, Francesca; Gubbins, Michael J; Ball, T.Blake; Kitching, Paul; Li, Yan; Kabani, Amin; Plummer, Frank
Title: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
  • Cord-id: 4wn40ivq
  • Document date: 2004_9_1
  • ID: 4wn40ivq
    Snippet: There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating an
    Document: There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.

    Search related documents:
    Co phrase search for related documents
    • acute sars respiratory syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
    • acute sars respiratory syndrome and mab inhibition: 1
    • acute sars respiratory syndrome and mabs binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • acute sars respiratory syndrome and mabs distinct: 1, 2, 3, 4
    • acute sars respiratory syndrome and mabs elisa reactivity: 1
    • acute sars respiratory syndrome and mabs exhibit: 1
    • acute sars respiratory syndrome and mabs identify: 1, 2, 3, 4
    • acute sars respiratory syndrome and mabs production: 1
    • acute sars respiratory syndrome and mabs react: 1, 2
    • acute sars respiratory syndrome and mabs reactive: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars respiratory syndrome and mabs reactivity: 1, 2, 3, 4, 5
    • acute sars respiratory syndrome and mabs recognise: 1
    • acute sars respiratory syndrome and mabs sars cov epitope specific: 1
    • acute sars respiratory syndrome and mabs target: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars respiratory syndrome and mabs total: 1